These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 15686787

  • 1. Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.
    Peters S, Trümmel M, Meyners W, Koehler B, Westermann K.
    Int J Cardiol; 2005 Feb 15; 98(2):331-5. PubMed ID: 15686787
    [Abstract] [Full Text] [Related]

  • 2. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
    Peters S.
    Am J Cardiovasc Drugs; 2008 Feb 15; 8(2):83-7. PubMed ID: 18422391
    [Abstract] [Full Text] [Related]

  • 3. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.
    Peters S, Götting B, Trümmel M, Rust H, Brattström A.
    J Invasive Cardiol; 2001 Feb 15; 13(2):93-7. PubMed ID: 11176015
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 15; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 6. Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions.
    Peters S, Koehler B, Steffen H, Rählert-Sommer A, Selbig D, Trümmel M.
    Int J Cardiol; 2010 Jun 25; 142(1):29-32. PubMed ID: 19419785
    [Abstract] [Full Text] [Related]

  • 7. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
    Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G, ORAR II Investigators.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1522-9. PubMed ID: 16630986
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, Kawamura A, Nishikawa H, Uehara Y, Saku K.
    Hypertens Res; 2009 Jul 18; 32(7):625-30. PubMed ID: 19461652
    [Abstract] [Full Text] [Related]

  • 9. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents.
    Peters S, Behnisch B, Heilmann T, Richter C.
    J Renin Angiotensin Aldosterone Syst; 2009 Jun 18; 10(2):91-5. PubMed ID: 19502256
    [Abstract] [Full Text] [Related]

  • 10. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, Mehran R, Russell ME, Stone GW, TAXUS-IV Investigators.
    J Am Coll Cardiol; 2005 Apr 19; 45(8):1186-92. PubMed ID: 15837247
    [Abstract] [Full Text] [Related]

  • 11. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 12. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Oct 20; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M, Ross H, Levesque S, Whittom L, Pelletier GB, Racine N, Meloche S, Voisin L.
    Ann Pharmacother; 2009 May 20; 43(5):831-9. PubMed ID: 19417110
    [Abstract] [Full Text] [Related]

  • 14. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2008 Apr 01; 71(5):594-8. PubMed ID: 18311841
    [Abstract] [Full Text] [Related]

  • 15. Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial.
    Kim YH, Lee CW, Hong MK, Park SW, Tahk SJ, Yang JY, Saito S, Santoso T, Quan L, Ge J, Weissman NJ, Lansky AJ, Mintz GS, Park SJ.
    Am Heart J; 2005 Feb 01; 149(2):336-41. PubMed ID: 15846274
    [Abstract] [Full Text] [Related]

  • 16. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 01; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 17. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
    Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW.
    J Am Coll Cardiol; 2005 Apr 19; 45(8):1165-71. PubMed ID: 15837244
    [Abstract] [Full Text] [Related]

  • 18. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun 19; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 19. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E.
    J Am Coll Cardiol; 2007 Oct 02; 50(14):1299-304. PubMed ID: 17903626
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.